Mangoceuticals (NASDAQ:MGRX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, FiscalAI reports. Mangoceuticals had a negative return on equity of 112.00% and a negative net margin of 4,639.13%.
Mangoceuticals Stock Performance
Shares of NASDAQ MGRX traded up $0.00 during mid-day trading on Thursday, reaching $0.53. 24,577,957 shares of the company’s stock were exchanged, compared to its average volume of 37,200,612. Mangoceuticals has a 52-week low of $0.16 and a 52-week high of $2.75. The company’s 50-day moving average is $0.42 and its 200-day moving average is $0.41.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Mangoceuticals during the fourth quarter worth about $25,000. Boothbay Fund Management LLC acquired a new position in shares of Mangoceuticals in the 4th quarter worth approximately $28,000. Jane Street Group LLC purchased a new position in shares of Mangoceuticals during the 4th quarter worth approximately $35,000. Geode Capital Management LLC boosted its position in shares of Mangoceuticals by 35.4% during the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock worth $40,000 after purchasing an additional 6,928 shares during the period. Finally, Ikarian Capital LLC acquired a new stake in Mangoceuticals in the 4th quarter valued at approximately $102,000. Institutional investors and hedge funds own 56.72% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on MGRX
About Mangoceuticals
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.
Featured Stories
- Five stocks we like better than Mangoceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
